IP Library Granted Patent US 7,601,514
Granted Patent B2
US 7,601,514 · App. 11/945,176 · Granted Oct 13, 2009

Nucleic acid encoding PRO10268 polypeptides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,601,514
App. No.
11/945,176
Granted
Oct 13, 2009
Kind
B2
Abstract

The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.

Claims (16)

1. An isolated nucleic acid comprising: (a) a nucleic acid sequence encoding the polypeptide shown in FIG. 16 (SEQ ID NO: 16); (b) a nucleic acid sequence encoding the polypeptide shown in FIG. 16 (SEQ ID NO: 16), lacking its associated signal peptide; (c) the nucleic acid sequence shown in FIG. 15 (SEQ ID NO: 15); (d) the full-length coding sequence of the nucleic acid sequence shown in FIG. 15 (SEQ ID NO: 15); or (e) the full-length coding sequence of the cDNA deposited under ATCC accession number PTA-1179, wherein the isolated nucleic acid encodes a polypeptide which inhibits the proliferation of T-lymphocytes.

2. The isolated nucleic acid of claim 1 comprising a nucleic acid sequence encoding the polypeptide shown in FIG. 16 (SEQ ID NO: 16).

3. The isolated nucleic acid of claim 1 comprising a nucleic acid sequence encoding the polypeptide shown in FIG. 16 (SEQ ID NO: 16), lacking its associated signal peptide.

4. The isolated nucleic acid of claim 1 comprising the nucleic acid sequence shown in FIG. 15 (SEQ ID NO: 15).

5. The isolated nucleic acid of claim 1 comprising the full-length coding sequence of the nucleic acid sequence shown in FIG. 15 (SEQ ID NO: 15).

6. The isolated nucleic acid of claim 1 comprising the full-length coding sequence of the cDNA deposited under ATCC accession number PTA-1179.

7. A vector comprising the nucleic acid of claim 1 .

8. The vector of claim 7 , wherein said nucleic acid is operably linked to control sequences.

9. An isolated host cell comprising the vector of claim 7 .

10. The host cell of claim 9 , wherein said cell is a CHO cell, an E. coli or a yeast cell.

11. An isolated nucleic acid that hybridizes under the high stringency conditions of 50% formamide, 5×SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5× Denhardt's solution, sonicated salmon sperm DNA (50 μg/ml), 0.1% SDS, and 10% dextran sulfate at 42° C., with washes at 42° C. in 0.2×SSC (sodium chloride/sodium citrate) and 50° C., formamide at 55° C., followed by a high-stringency wash consisting of 0.1×SSC containing EDTA at 55° C. to:

(a) a nucleic acid sequence encoding the polypeptide shown in FIG. 16 (SEQ ID NO: 16);

(b) a nucleic acid sequence encoding the polypeptide shown in FIG. 16 (SEQ ID NO: 16), lacking its associated signal peptide;

(c) the nucleic acid sequence shown in FIG. 15 (SEQ ID NO: 15);

(d) the full-length coding sequence of the nucleic acid sequence shown in FIG. 15 (SEQ ID NO: 15); or

(e) the full-length coding sequence of the cDNA deposited under ATCC accession number PTA-1179.